Microfluidics Versus Gradient Centrifugation Effect on Euploidy Rates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-13

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research is being done to determine if using a microfluidics chamber, a device used to process sperm, will be effective in improving the rates of embryos with normal chromosomes (structures that carry genetic information) during in vitro fertilization (IVF) treatment. The investigators hypothesize that this device is effective at improving rates of normal chromosomes among embryos.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing

NCT06023472

Infertility Genetic Disease Chromosomal Rearrangement +1 more

RECRUITING NA

A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence

NCT07062237

Infertility Male Factor Infertility

RECRUITING NA

Sperm Selection and Embryo Development: Comparison of the Density Gradient Centrifugation and Microfluidic Chip Sperm Preparation Methods Sperm Selection and Embryo Development: Comparison of the Density Gradient Centrifugation and Microfluidic Chip Sperm Preparation Methods

NCT04962074

Reduced Sperm Motility IVF ICSI +1 more

COMPLETED NA

Microfluidics Versus Density Gradient Centrifugation for Sperm Preparation in IVF

NCT07004309

Male Infertility Sperm DNA Fragmentation In Vitro Fertilization (IVF)

COMPLETED NA

A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI

NCT04818593

ART

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As part of the in vitro fertilization (IVF) process, eggs are removed from the ovaries and are inseminated (mixed) or injected with sperm. In order for fertilization to occur, the sperm cells must be separated from the semen before introducing them to the eggs. Currently, sperm are isolated from the semen using a series of wash steps in a centrifuge (device to spin and concentrate the sperm). This requires processing at high speeds in order to separate motile sperm from the other parts of the semen. Although it is common practice, it is possible that this method of processing the semen may cause damage to the sperm cells.

Alternatively, a microfluidics chamber can be used to choose the best sperm. A microfluidics chamber is a small device in which the unwashed sperm can be placed at one end. Sperm that are moving forward will swim through the chamber and come out the other end. Dead sperm are left behind and the sperm with the best motility (how normally they move forward) and normal morphology (how the sperm looks) will make it to the other end of the chamber. These sperm can then be chosen for injection into the egg. This device is FDA-approved for this purpose and is commercially available and is currently routinely used in the IVF lab utilized by the investigators as well as most labs in the country.

Some small initial studies showed that a higher number of embryos with higher quality were made with sperm selected from a microfluidics chamber. In another recent study, the chances of creating an embryo with a normal number of chromosomes (structures that carry genetic information) was also slightly higher if a microfluidics chamber was used to process the sperm. This might be because sperm that have the highest motility and normal morphology may also be more likely to be genetically normal. However, there are no good-quality studies looking at the rates of embryos with normal chromosomes created from using a microfluidics chamber to process sperm.

The purpose of this research study is to determine whether using a microfluidics chamber to process sperm for injection into eggs increases the rates of embryos with normal chromosomes. At the time of egg retrieval, participants will have their eggs randomized (like the flip of a coin) into two groups. Half of the eggs will be injected with sperm processed using gradient centrifugation, the standard method. The other half of the eggs will be injected with sperm processed using a microfluidics chamber. The goal is to determine the rate of embryos with normal chromosomes in each group. Other goals include looking at how many embryos develop to good quality blastocysts and are biopsied and how many patients get pregnant after embryo transfer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Recurrent Pregnancy Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Sibling oocyte study: Participants will have their oocytes (eggs) divided into two groups. Half of the eggs will be injected with sperm processed in the normal way, and half will be injected with sperm processed via a microfluidics chamber.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Participants, clinical providers, investigators and Outcome assessors will be blinded to outcomes.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microfluidics

Half of participants eggs will be injected with sperm processed using a microfluidics chamber.

Group Type EXPERIMENTAL

Microfluidics chamber

Intervention Type DEVICE

Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.

Density gradient centrifugation

Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).

Group Type ACTIVE_COMPARATOR

Density Gradient Centrifugation

Intervention Type OTHER

Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microfluidics chamber

Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.

Intervention Type DEVICE

Density Gradient Centrifugation

Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ZyMot Fertility (device brand name)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects are nonpregnant females ≥ 18 years and ≤ 42 years of age.
* Subjects obtain ≥ 6 mature oocytes at the time of oocyte retrieval or at the time of ICSI.
* Subjects are utilizing ICSI for fertilization.
* Subjects are utilizing PGT-A (PGT for aneuploidy).
* Subjects are able to understand, read, and write in English at a fifth-grade level.
* Subjects are willing to comply with study protocol and procedures and provide written informed consent.

Exclusion Criteria

* Subjects are utilizing donor oocytes, donor sperm, or gestational carrier.
* Subjects have a diagnosis of severe male factor infertility (sperm concentration \< 5 mil/mL at semen analysis).
* Subjects are utilizing surgically removed sperm (e.g. via testicular sperm aspiration \[TESA\] or microsurgical epididymal sperm aspiration \[MESA\]).
* Subjects are utilizing frozen/thawed sperm.
* Subjects are utilizing frozen/thawed oocytes.
* Subjects are undergoing a day 3 (cleavage stage) embryo transfer.
* Subjects obtain \< 6 mature oocytes at the time of oocyte retrieval or at the time of ICSI.
* Subjects obtain ≥ 6 mature oocytes but choose to fertilize fewer than 6 of them.
* Sperm sample parameters are low on the day of oocyte retrieval (semen volume \< 1.0 mL or concentration \< 1 million motile/mL).
* Male partner has an infectious disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No